

## 2026 Special General Meeting

### Absentee Voting Card

Remote voting card for the extraordinary general meeting of shareholders of Oncomatrix Biopharma, S.A., to be held in person at the company's registered office, located at Parque Tecnológico de Vizcaya, 801-B-2º, Derio (Bizkaia) (zip code 48160), with the option to attend remotely, on September 16, 2026, at 12:00 p.m. (CEST), in a single meeting.

|                                                |                      |
|------------------------------------------------|----------------------|
| <b>Shareholder's full name or company name</b> |                      |
|                                                |                      |
| <b>Number of shares</b>                        | <b>Share numbers</b> |
|                                                |                      |

### Remote voting

The shareholder holding the shares indicated above exercises their voting rights in favor of all proposals made by the board of directors regarding the items on the attached agenda, unless a different voting preference is indicated below (*check the corresponding boxes*). Voting prior to the general meeting is not permitted for any proposals not included on the agenda:

| Agenda Item | 1(*) | 2 | 3 | 4(*) | 6 | 7 | 8(*) |
|-------------|------|---|---|------|---|---|------|
| In favor    |      |   |   |      |   |   |      |
| Against     |      |   |   |      |   |   |      |
| Abstention  |      |   |   |      |   |   |      |
| Blank       |      |   |   |      |   |   |      |

(\*): Items for informational purposes only; therefore, they are not subject to a vote

### Signature of the shareholder granting the proxy

In ....., on ..., 2026

## **Remote Voting**

Shareholders may exercise their voting rights by mail, email, or any other means of remote communication. To cast a vote by mail, the shareholder must complete and sign the voting card, a sample of which will be available on the Company's website ([www.oncomatryx.com](http://www.oncomatryx.com)), indicating their vote—in favor, against, abstention, or a blank vote—by placing a check mark in the corresponding box.

The completed and signed ballot must be sent to Oncomatryx Biopharma, S.A. by mail to Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (zip code 48160) or by email to the Chairman at [shareholders@oncomatryx.com](mailto:shareholders@oncomatryx.com). A shareholder who casts a vote by mail and fails to mark any or all of the boxes intended to indicate a vote on the agenda items shall be deemed to wish to vote in favor of the respective proposals made by the Board of Directors.

A vote cast by mail shall be rendered null and void by a subsequent and express revocation by the shareholder, made through the same means used to cast the vote and within the established deadline for voting, or by the personal attendance at the General Shareholders' Meeting of the shareholder who cast the vote by mail or by the attendance of their representative.

Votes cast by mail must be received by the Company no later than 11:59 p.m. on the day prior to the date scheduled for the General Shareholders' Meeting, that is, no later than 11:59 p.m. on September 15, 2026. Otherwise, the vote shall be deemed not to have been cast. After the aforementioned deadline, only in-person votes cast at the General Shareholders' Meeting by the shareholder in person or by a shareholder validly representing them will be accepted. A shareholder who casts their vote remotely by mail shall be considered present for the purposes of establishing a quorum for the General Shareholders' Meeting.

## **AGENDA**

- First. -** Reduction of the Company's share capital through the redemption of four hundred sixty-eight thousand five hundred fifty-two (468,552) treasury shares.
- Second. -** Appointment, for the term provided for in the bylaws, of Fundación Bancaria Kutxa-Kutxa Banku Fundazioa as a member of the Company's Board of Directors.
- Third. -** Setting the maximum number of directors, within the minimum and maximum limits established in the articles of incorporation.
- Fourth. -** Amendment of Article 25 of the Company's articles of incorporation, effective January 1, 2027.  
Replacement of the CEO's variable compensation.
- Fifth. -** Approval of the maximum compensation for the CEO, effective January 1, 2027.
- Sixth. -** Determination of the CEO's compensation effective January 1, 2027.
- Seventh. -** Delegation of powers.
- Eighth. -** Drafting, reading, and, if applicable, approval of the minutes of the meeting.